Department of Pathology, The Second Hospital of Jilin University, 218 Ziqiang Road, 130041, Changchun, Jilin, China.
BMC Cancer. 2023 Feb 16;23(1):161. doi: 10.1186/s12885-023-10619-6.
The classification of thymomas is based on the morphology of epithelial tumor cells and the proportion of lymphocytes. Type A thymomas are composed of the spindle or oval tumor epithelial cells. Tumor cells of B thymomas are epithelioid-shaped with increasing atypia. Type AB thymomas have the features of epithelial tumor cells of A and B thymomas. The diagnosis can be difficult because of the complex morphology. Some novel thymic epithelial markers have been reported in several preclinical studies, but they have not been applied to clinical practice. Here, we investigated the expression of 3 cortical and 3 medullary markers, which are thymoproteasome-specific subunit β5t (β5t), thymus-specific serine protease 16 (PRSS16), cathepsin V, autoimmune regulator (AIRE), CD40 and claudin-4.
Immunohistochemistry was used to analyze 53 cases of thymomas and thymic squamous cell carcinomas (TSCC), aiming to explore the expression of cortical and medullary epithelial markers and their correlation with histological classification, Masaoka-Koga stage, and prognosis.
Our results found that for cortical epithelial markers the expression of β5t, PRSS16, and cathepsin V was higher in type AB and B thymomas than in micronodular thymoma with lymphoid stroma (MNT), and we observed a dramatic increase of β5t and PRSS16 expression in type AB compared to type A thymomas. In medullary epithelial markers, the expression of AIRE was higher in type A than in B3 thymomas. CD40 and β5t expression were associated with the Masaoka-Koga stage. High cathepsin V expression was related to a good prognosis and a longer progression-free survival.
This is the first comprehensive analysis of the role of thymic cortical and medullary epithelial markers as biomarkers for differential diagnosis and prognosis in thymic tumors. Thymic medullary epithelial immunophenotype was found to exhibit in type A, MNT, and TSCC. Type B thymomas primarily exhibited a cortical epithelial immunophenotype. Type AB thymomas showed cortical, medullary, or mixed corticomedullary epithelial immunophenotype. Our results demonstrated that thymic cortical and medullary epithelial markers including β5t, PRSS16, cathepsin V, and AIRE could be used as ancillary markers in the diagnosis and prognosis of thymic epithelial tumors.
胸腺瘤的分类基于上皮肿瘤细胞的形态和淋巴细胞的比例。A型胸腺瘤由梭形或椭圆形肿瘤上皮细胞组成。B 型胸腺瘤的肿瘤细胞呈上皮样,异型性增加。AB 型胸腺瘤具有 A 型和 B 型胸腺瘤上皮肿瘤细胞的特征。由于形态复杂,诊断可能具有挑战性。一些新的胸腺癌上皮标志物已在几项临床前研究中报道,但尚未应用于临床实践。在这里,我们研究了 3 种皮质和 3 种髓质标志物的表达,它们是胸腺蛋白酶体特异性亚基β5t(β5t)、胸腺特异性丝氨酸蛋白酶 16(PRSS16)、组织蛋白酶 V、自身免疫调节剂(AIRE)、CD40 和 Claudin-4。
免疫组织化学用于分析 53 例胸腺瘤和胸腺癌(TSCC),旨在探索皮质和髓质上皮标志物的表达及其与组织学分类、Masaoka-Koga 分期和预后的关系。
我们的结果发现,对于皮质上皮标志物,AB 型和 B 型胸腺瘤中β5t、PRSS16 和组织蛋白酶 V 的表达高于微结节性淋巴基质胸腺瘤(MNT),并且我们观察到 AB 型胸腺瘤中β5t 和 PRSS16 的表达明显高于 A 型胸腺瘤。在髓质上皮标志物中,A 型胸腺瘤中 AIRE 的表达高于 B3 型胸腺瘤。CD40 和β5t 的表达与 Masaoka-Koga 分期有关。高组织蛋白酶 V 表达与预后良好和无进展生存期延长有关。
这是首次全面分析胸腺皮质和髓质上皮标志物作为胸腺瘤鉴别诊断和预后的生物标志物的作用。在 A 型、MNT 和 TSCC 中发现了胸腺髓质上皮免疫表型。B 型胸腺瘤主要表现为皮质上皮免疫表型。AB 型胸腺瘤表现为皮质、髓质或混合皮质髓质上皮免疫表型。我们的结果表明,β5t、PRSS16、组织蛋白酶 V 和 AIRE 等胸腺皮质和髓质上皮标志物可作为胸腺癌上皮肿瘤的辅助诊断和预后标志物。